See the latest news and media coverage for IGC Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotechnology company developing Alzheimer’s treatments and AI health tools
igcpharma.comLast updated
In short: IGC Pharma completed CALMA trial enrollment, with topline results expected in Q4 2026.
The new application layer extends the MINT-AD model to support early risk assessment, cognitive monitoring, and trial optimization across healthcare and consumer markets.
The company enhances capabilities and partners with OPIS Research to support FDA and EMA engagement ahead of Q4 2026 results.
The company reviews potential damages from the 2018 short campaign targeting IGC, following findings of securities fraud.
CEO Ram Mukunda and CFO Claudia Grimaldi acquired 4.27 million shares at $0.27 per share by canceling debt owed to them.
Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 ...
POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments...
Artificial Intelligence is rapidly transforming drug discovery, clinical research, and Alzheimer's disease development, and IGC Pharma, Inc. (NYSE: IGC) is positioning itself at the forefront...
Senior management elects restricted common stock at $0.27 per share in lieu of repayment of amounts owed, including...
Track IGC Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to IGC Pharma and other trending companies.
